Timothy M. Lestingi

1.1k total citations
26 papers, 844 citations indexed

About

Timothy M. Lestingi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Timothy M. Lestingi has authored 26 papers receiving a total of 844 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Timothy M. Lestingi's work include Prostate Cancer Treatment and Research (15 papers), Multiple Myeloma Research and Treatments (4 papers) and Cancer Treatment and Pharmacology (4 papers). Timothy M. Lestingi is often cited by papers focused on Prostate Cancer Treatment and Research (15 papers), Multiple Myeloma Research and Treatments (4 papers) and Cancer Treatment and Pharmacology (4 papers). Timothy M. Lestingi collaborates with scholars based in United States. Timothy M. Lestingi's co-authors include E Gupta, Jesús Ramı́rez, MJ Ratain, Rosemarie Mick, Everett E. Vokes, Xiaolin Wang, Chadi Nabhan, Jon Richards, Nilesh Mehta and Jacob D. Bitran and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and British Journal of Cancer.

In The Last Decade

Timothy M. Lestingi

25 papers receiving 812 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Timothy M. Lestingi United States 11 599 560 179 82 77 26 844
Isabelle Hennebelle France 19 506 0.8× 726 1.3× 188 1.1× 40 0.5× 52 0.7× 25 1.1k
Ronald Drengler United States 13 296 0.5× 487 0.9× 104 0.6× 68 0.8× 60 0.8× 27 701
Lisa Iacono United States 14 320 0.5× 278 0.5× 200 1.1× 68 0.8× 23 0.3× 34 761
Douglas Bootle Switzerland 13 718 1.2× 582 1.0× 304 1.7× 95 1.2× 31 0.4× 17 1.2k
Tomohide Tamura Japan 19 726 1.2× 522 0.9× 267 1.5× 29 0.4× 59 0.8× 44 1.2k
A Pourtier-Manzanedo France 8 437 0.7× 475 0.8× 183 1.0× 145 1.8× 21 0.3× 10 827
Jean‐Claude Marshall United States 18 440 0.7× 251 0.4× 112 0.6× 23 0.3× 118 1.5× 31 782
Norman Pratt United Kingdom 11 284 0.5× 516 0.9× 200 1.1× 44 0.5× 34 0.4× 14 958
Maura A. Kraynak United States 13 308 0.5× 431 0.8× 153 0.9× 59 0.7× 17 0.2× 19 807
Lorrin Yee United States 17 446 0.7× 514 0.9× 128 0.7× 43 0.5× 217 2.8× 37 1.0k

Countries citing papers authored by Timothy M. Lestingi

Since Specialization
Citations

This map shows the geographic impact of Timothy M. Lestingi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy M. Lestingi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy M. Lestingi more than expected).

Fields of papers citing papers by Timothy M. Lestingi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy M. Lestingi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy M. Lestingi. The network helps show where Timothy M. Lestingi may publish in the future.

Co-authorship network of co-authors of Timothy M. Lestingi

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy M. Lestingi. A scholar is included among the top collaborators of Timothy M. Lestingi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy M. Lestingi. Timothy M. Lestingi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lestingi, Timothy M., et al.. (2020). Medicare compared with private insurance for the treatment of cancer.. Journal of Clinical Oncology. 38(15_suppl). e19033–e19033. 1 indexed citations
2.
Green, Linda K., et al.. (2018). An Attempt to Quantitate “Value” In Medical Oncologic Therapy. Cureus. 10(6). e2810–e2810. 1 indexed citations
3.
Dalal, Neil, et al.. (2015). Copper deficiency mimicking myelodysplastic syndrome. Clinical Case Reports. 3(5). 325–327. 5 indexed citations
4.
Meyer, Andrew, et al.. (2013). Role of Sorafenib in Overcoming Resistance of Chemotherapy-Failure Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 12(2). 100–105. 13 indexed citations
5.
Nabhan, Chadi, et al.. (2013). Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study. Clinical Genitourinary Cancer. 12(1). 27–32. 15 indexed citations
6.
Sulo, Suela, et al.. (2013). A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer. British Journal of Cancer. 109(7). 1711–1716. 45 indexed citations
7.
Nabhan, Chadi, et al.. (2012). Overcoming chemotherapy resistance in patients (pts) with chemotherapy-failure, castration-resistant prostate cancer (CRPC) with sorafenib.. Journal of Clinical Oncology. 30(5_suppl). 127–127. 1 indexed citations
8.
9.
Nabhan, Chadi, Dana Villines, Timothy M. Lestingi, et al.. (2012). Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. British Journal of Cancer. 107(4). 592–597. 16 indexed citations
10.
11.
12.
Bitran, Jacob D., et al.. (2009). Maintenance GM-CSF in patients with castration-resistant prostate cancer (CRPC) who maximized their response to chemotherapy. Journal of Clinical Oncology. 27(15_suppl). e16155–e16155. 1 indexed citations
13.
Lestingi, Timothy M., et al.. (2008). A phase II study with single agent erlotinib in chemotherapy-naïve androgen independent prostate cancer (AIPC). Journal of Clinical Oncology. 26(15_suppl). 16104–16104. 1 indexed citations
14.
15.
Richards, Jon, et al.. (1999). Combination of Chemotherapy With Interleukin-2 and Interferon Alfa for the Treatment of Metastatic Melanoma. Journal of Clinical Oncology. 17(2). 651–651. 74 indexed citations
16.
Gupta, E, Rosemarie Mick, Jesús Ramı́rez, et al.. (1997). Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.. Journal of Clinical Oncology. 15(4). 1502–1510. 153 indexed citations
17.
Mick, Rosemarie, Everett E. Vokes, Timothy M. Lestingi, et al.. (1996). Etoposide combined with interferon alfa-2b: Novel exploitation of established etoposide pharmacokinetics and pharmacodynamics*. Clinical Pharmacology & Therapeutics. 59(3). 349–359. 1 indexed citations
18.
Vogelzang, Nicholas J., Timothy M. Lestingi, & Gary S. Sudakoff. (1994). Phase I Study of Immunotherapy of Metastatic Renal Cell Carcinoma by Direct Gene Transfer into Metastatic Lesions. University of Chicago, Chicago, Illinois. Human Gene Therapy. 5(11). 1357–1370. 17 indexed citations
19.
Gupta, E, Timothy M. Lestingi, Rosemarie Mick, et al.. (1994). Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.. PubMed. 54(14). 3723–5. 409 indexed citations
20.
Lestingi, Timothy M., et al.. (1993). Philadelphia Chromosomepositive Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America. 7(1). 161–175. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Isabelle Hennebelle Breakdown of academic impact, for papers by Ronald Drengler Breakdown of academic impact, for papers by Lisa Iacono Breakdown of academic impact, for papers by Douglas Bootle Breakdown of academic impact, for papers by Tomohide Tamura Breakdown of academic impact, for papers by A Pourtier-Manzanedo Breakdown of academic impact, for papers by Jean‐Claude Marshall Breakdown of academic impact, for papers by Norman Pratt Breakdown of academic impact, for papers by Maura A. Kraynak Breakdown of academic impact, for papers by Lorrin Yee
Rankless by CCL
2026